AIM AIM ImmunoTech

AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

OCALA, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced Chris McAleer, Ph.D., Deputy Chief Science Officer of AIM, and William Mitchell, M.D. Ph.D., Chairman of the Board of Directors of AIM, will present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 8-10, 2022. In addition to management’s presentations, the Company is proud to announce its sponsorship of the event.

Presentation Details:

Title: Rintatolimod (Ampligen®): An Investigational Immunomodulatory Agent Targeted at Cancers of High Unmet Need

Author: Christopher McAleer, Ph.D.

Date: Saturday, September 10

Title: The Mechanism of PAMP Restricted Rintatolimod in Limiting Systemic Inflammatory Responses

Author: William M. Mitchell, M.D., Ph.D.

Date: Saturday, September 10

Presentations will take place at the Cancer Genetics & Pharmacology Building at the Roswell Park Comprehensive Center.

For more information about the conference, visit: .

The presentations will be available on the AIM once presented at the conference.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The Company’s lead product, Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.



For more information, please visit and connect with the Company on , , and .



Investor Relations Contact
JTC Team, LLC
Jenene Thomas 
833-475-8247
EN
06/09/2022

Underlying

AIMAIM ImmunoTech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM ImmunoTech

 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at...

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists OCALA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (OTC Pink: AIMI) (“AIM” or the “Company”) today announced the presentation of clinical trial data involving AIM’s drug Ampligen by Pawel Kalinski, MD, PhD, at the recent held May 3-7, 2025, in Honolulu, HI. The paper, titled “Systemic Infusion of dsRNA (Rintatolimod) plus IFN Promotes Selective Influx of CTLs (but not Treg) into the TME — Counteracting Chemokine Heterogeneity of...

May 8, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Ope...

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (OTC Pink: AIMI) — an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19 — announced that as of today its common stock is trading under the ticker AIMI on the Pink Open Market and the Special Meeting on April 30, 2025, about a reverse split is still on. For additional information, refer to AIM’s Defini...

April 7, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal OCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, reported that on April 4, 2025, it received notification from NYSE Regulation of the NYSE American LLC (the “NYSE American” or the “Exchange”) that it had suspended trading of the Company’s common stock and of its determination to comme...

April 4, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Res...

AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by collaborators AstraZeneca (pancreatic cancer) and Merck (advanced ovarian cancer) Company to host conference call and webcast on Tuesday, April 1st at 8:30 AM ET O...

March 27, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘2...

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference Includes latest updates on pancreatic cancer and bird flu clinical trials OCALA, Fla., March 11, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced its participation in the Virtual Investor “. As part of the event, AIM CEO Thomas K. Equels presented his top five reasons why he believes the investment community and industry colleagues should pay attention to the Company in 2025: Progress in late-stage pancreatic cancer treatment with significant advancemen...

March 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch